I am Seeking Alpha's CEO and Editor-in-Chief. My love for the stock markets goes back to when I was a kid. Who else remembers combing through the stock quotes at the back of the business section of your local paper?
I joined Seeking Alpha in 2006 and launched Wall Street Breakfast and Market Currents, our top-of-class short-form breaking news for investors. In 2010 I became editor-in-chief and in 2015 I became CEO.
I live in Jerusalem with my wife and a bunch of exceptional kids. Most days, you'll find me making the commute from Jerusalem to Raanana. Occasionally I get to work from my home-office, from where I keep an eye on the beautiful Judean Hills.
To contact me, send me a direct message, or email me at firstname.lastname@example.org.
My name is Payman Winborn. Upon graduation from college in 1999 I founded a company that distributed computer hardware. Although this was a profitable business, I did not want to focus all my resources on one avenue of success, so I looked to diversify my interests. I explored real estate and finance as possible alternative businesses and discovered an interest and passion in futures trading. This is what I ultimately choose as a second source of income.
Initially, I imagined that day trading would be the ideal profession: no customers or staff, no inventory or rent and the possibility of unlimited income. And, more importantly, it presented me with the opportunity to work anywhere....from the privacy of my home or from the balcony of a hotel room overlooking the Pacific Ocean.
Unfortunately, I knew little about the pitfalls of day trading for a living. To begin with, I spent countless hours reading books, studying charts and conducting research in an effort to become a profitable trader. Six years later, and after the loss of several hundred thousand dollars, my efforts finally resulted in the development of a highly profitable strategy.
This strategy is primarily based on technical analysis and was developed for ES E-Mini S&P 500 Futures contracts from CME Group but it also works in many other financial instruments such as Stocks (NYSE), Bonds, Currencies(Forex Spot), Commodities (Gold and Crude Oil From CME GROUP,Globex,NYMEX, CBOT,Brent Crud Oil From ICE Global Markets), Options, Global Indices and CFD’s with similar high accuracy.
In retrospect, I understand that the biggest barrier to my success was the fact that I tried to learn everything by myself. An experienced mentor could have helped me avoid that painful learning experience....and saved me a significant amount of money as well as many years of frustration.
Today I am an active, and profitable, trader. As a token of appreciation for my success, I now share my tools and experience with other day traders. I believe that my knowledge and skill can help others become successful traders and, in the summer of 2010, I began to publish my realtime market signals and daily results online in order to demonstrate the accuracy of my trading strategy.
I am a Financial Analyst and maintain my own Site http://www.everythingaboutinvestment.com where i put the articles regarding investment so that it can help each and everyone around the globe to get an detail insight into Investing and Investment.
Technical Analysis & Japanese Candlesticks Trader as a full time job, over 15 years of experience, combining with fundamentals and thorough DD to find the best entry & exit points, Biotech sector expert, following this sector for over 4 years, trading the clinical catalyst & following the stocks runup till the catalyst day.
Have been an investor for 60 years. Last 20 years have concentrated on biotechs. Have been senior exec with Shell and ITT before retiring 30+ years ago. My working areas were finance, informatics and international management. Taught MBA courses in management, informatics and communications. Speak French and Spanish plus some German.
Andrew McDonald is a healthcare investment professional with expertise in identifying transformative medicines as well as in forecasting clinical trial, regulatory, and sales outcomes. Prior to co-founding LifeSci Advisors, Andrew most recently served as senior biotechnology analyst at Great Point Partners, a dedicated life science hedge fund. From 2004-2006, Andrew was Co-head of Healthcare Research and Biotechnology Analyst at ThinkEquity Partners, a boutique investment bank. Prior to entering the financial services industry, Andrew was a medicinal chemist at Cytokinetics from 2001-2004, where he discovered and developed a promising anti-cancer agent now in clinical trials. Andrew began his pharmaceutical career as a medicinal chemist at Pfizer from 2000-2001. Andrew received a Ph.D. in organic chemistry from UC Irvine and completed his B.S. in chemistry at UC Berkeley.
Steven currently focuses his analyses primarily on the valuation of smaller biotechs (100MM to 1 BB market cap) and utilizes all sources of information, including conversations with management, peer-reviewed publications, SEC filings, and all available primary and secondary research.
Steven is currently a consultant for a New York based life science focused consultancy, and brings a strong scientific and financial background to his current position.
Previously, Steven earned a Ph.D. from the Scripps Research Institute and an M.A. from Columbia University, with extensive work in the field of synthetic and medicinal chemistry, publishing several papers in prestigious peer-reviewed journals. He is also pursuing the CFA designation, and has completed exam level 2.
Please email me with any questions, comments, and investment ideas. (stevenb29 at gmail.com)
The founding members of Chimera Research Group have over 50 years of combined experience in the biotech and pharmaceutical sector. Their experience includes work at Investment Banks, Hedge Funds, Pharmaceutical Companies, top-tier Universities, and the U.S. Food and Drug Administration (FDA). Their published work includes freelance and editorial contributions both print and on-line, clinical and medical research, books and tutorials, as well as contributions to on-line social media. Through these and other activities they were able to collaborate and connect amongst themselves to establish this cadre of like-minded biotech/pharma trading and investing aficionados.
The Team includes:
Chief Scientific Analyst - Jason Chew
Chief Research Analyst - Patrick Crutcher
Chief Medical Analyst - Dr. Tro Kalayjian
CEO & Trading Analyst - Tony Pelz
Research Analyst - Dr. Andrew Goodwin
Research Analyst - Dr. Juan Pedro Rodríguez Serrate
Technical Analyst - Joe Gantoss
Research Analyst - Dr. Steven Murphy
Retired from engineering/management since 1997. Largely biotech, but some other stocks and real estate investor for over 25 years. Enjoy skiing, sailing, sports. I enjoy the role of Devil's Advocate, so some of what I say may be to provoke discussion, and may not reflect my actual opinion.
I'm currently undergoing treatment for Acute Lymphoblastic Leukemia. I had planed to be skiing now, but sometimes life gets in the way of your plans. While I'm confident of achieving remission, I intend to be very critical of the FDA for the way drug testing is done. I'm strongly in favor of streamlining the clinical trial process, especially when related to drugs for potentially terminal diseases. I am scheduled for stem cell transplantation late this month (4/15).
M.E. Garza is one of the founders of the biotech and healthcare sector news portal BioMedReports.com. He believes in getting the news from credible sources on the street and often reaches out to CEOs and newsmakers directly for interviews and discussions about their companies. Since he began publishing in 2008, Garza has built a reputation as a writer and reporter who can move markets. His track record for accurately reporting rumors and alerting readers about developments in the biotech/healthcare sector is unmatched during that time.
I am film and television producer who writes a value investing oriented blog called Chromainvesting.com. I try to explore the Deep value orientation of Graham, with an updated perspective that includes the work of Behavioural Finance gurus such as James Montier.
I am a small-time writer/blogger who dreams big and enjoys researching and writing about biotechs and pharmaceuticals. My work experiences include food safety, water quality, pesticides, food additives, paints, plastics and pharmaceutical precursors. My focus as of late has been researching the treatment options for many cancers and prevention of their recurrence. Additional recent research has been in the stem cell field, an exciting field in its infancy but now becoming a teenager! My ongoing goal for investors is attempting to find under-the-radar or oversold pharmaceuticals or biotechs for investment potential.